/ Not yet recruitingEarly Phase 1IIT A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of mRNA encoding CD19/CD3 T cell engager (ABO2203) in patients with refractory autoimmune diseases who received inadequate response or relapsed from standard of care (SoC). The trial included dose escalation and dose expansion parts.
100 Clinical Results associated with Suzhou Guangxin Biotechnology Co., Ltd.
0 Patents (Medical) associated with Suzhou Guangxin Biotechnology Co., Ltd.
100 Deals associated with Suzhou Guangxin Biotechnology Co., Ltd.
100 Translational Medicine associated with Suzhou Guangxin Biotechnology Co., Ltd.